Zervira Tablet

Zervira tablet is indicated for the treatment of herpes simplex, recurrent herpes simplex and herpes zoster. Its unique mechanism of action makes it a potential alternative for patients who have developed resistance to other antiviral medications.

Amenamevir works by inhibiting the viral helicase-primase complex, an enzyme essential for unwinding the viral DNA and synthesizing primers during viral DNA replication. This mechanism is distinct from traditional antiviral drugs like acyclovir and valaciclovir, which target viral DNA polymerase.

Herpes simplex: The usual adult dosage of Amenavir is 200 mg administered orally once daily after meal.

Recurrent herpes simplex: 1200 mg single dose after meals within 6 hours after the appearance of the initial symptoms of recurrent herpes simplex. (Only one dose is required).

Herpes zoster: The usual adult dosage of Amenavir is 400 mg administered orally once daily after meal.

Use in children: There is a lack of specific clinical studies evaluating the safety and efficacy of Amenamevir in children.

Zervira has notable interactions with certain drugs due to its metabolism via cytochrome P450 enzymes, particularly CYP3A4.

Ketoconazole: As a strong CYP3A4 inhibitor, Ketoconazole significantly increases the plasma concentration of Zervira.

Rifampicin:This strong CYP3A4 inducer markedly decreases Zervira levels, that could lead to reduced efficacy of Zervira.

Midazolam: As a substrate of CYP3A4, Midazolam's pharmacokinetics are affected by Zervira, leading to decreased plasma levels when both are taken together.

Warfarin: No significant interaction was observed between Zervira and Warfarin, a medication metabolized by CYP2C9.

Amenamevir is contraindicated in patients with:

• Severe Renal Impairment.
• A history of hypersensitivity of Amenamevir or any component of the preparation.

Common Side Effects are Headache, Nausea, Diarrhea, Abdominal Pain, Skin Reaction, increased N-acetyl-(M>glucosaminidase and a1-microglobulin levels Serious Side Effects are Thrombocytopenia, Gingival Bleeding, Palpitations.

Pregnancy: Animal studies in mice and rabbits showed no adverse effects on maternal animals or fetal development at certain doses. However, the report does not provide specific recommendations regarding the safety of Amenamevir in pregnant women.

Lactation: There is no specific information about the use of Amenamevir during breastfeeding.

Special monitoring is essential for patients with the following clinical conditions:

• Severe renal impairment
• Thrombocytopenia
• Elderly patients

Anti-viral drugs

Store below 30°C in a dry place. Keep all medicine out of reach of children. Keep away from light & moisture.